AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy.
Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy.
Laboratory for Multidisciplinary Research, Institute of Nuclear Sciences VINCA, Belgrade, Yugoslavia. eveljkve@ubbg.etf.bg.ac.yu
V
V
Veljkovic
R
R
Metlas
H
H
Köhler
H B
HB
Urnovitz
J
J
Prljic
N
N
Veljkovic
E
E
Johnson
S
S
Müller
D016915:AIDS Vaccines / Q000009:adverse effects / Q000302:isolation & purification / Q000494:pharmacology*; D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004196:Disease Outbreaks / Q000517:prevention & control; D015321:Gene Rearrangement; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D011995:Recombination, Genetic
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120